enVVeno Medical Corp

NASDAQ:NVNOUnited States

enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.

Contact Information

Headquarters

70 DopplerIRVINE, CA, United States 92618-4306

Phone

949-261-2900

Fax

949-261-2992

Executives

Chief Executive Officer, Director

Robert Berman

Chief Financial Officer, Treasurer

Craig Glynn

Senior Vice President, Chief Technology Officer

Hamed Alavi

Senior Vice President, Chief Medical Officer

Marc Glickman

Chief Commercial Officer

Andrew Cormack